Eyeworld

13 EW ASCRS NEWS December 2016 both well respected in their fields," Dr. Obstbaum said. "We worked at perpetuating the idea that this magazine was something that a reader could look at to get good and balanced information, rather than just being presented a singular point of view." Modern magazine Eric Donnenfeld, MD, EyeWorld's current chief medical editor, said that the magazine has expanded well beyond its early confines. "EyeWorld started as the magazine that represented ASCRS and was distributed all over the U.S.," he said, adding that it rapidly became the premier periodical for those who wanted to stay abreast of the latest issues in cataract and refrac- tive surgery, as well as all of anterior segment surgery. However, it has grown beyond this important initial role. "It has progressed to where it has become an international maga- zine, with distribution all over the world, and has also gone digital," he said. "It is readily available anytime, anywhere that a person has a smart- phone or a tablet." Readers now have access to the latest information in ophthalmology whenever they choose. There's now a synergy between the troves of digital media available from ASCRS and EyeWorld articles. "You can read about the surgical technique and then watch the technique from the ASCRS libraries," Dr. Donnenfeld noted, adding that as a result, EyeWorld has even more tightly aligned itself with ASCRS as an important educational vehicle. EyeWorld has become an im- portant agent in the educational pathway in ophthalmology, Dr. Donnenfeld said. "EyeWorld is now universally recognized as provid- ing the best quality education in anterior segment surgery thanks to the long tradition of education utilizing boards of both ASCRS and EyeWorld," he said. "We're creat- ing pathways where education has moved from one meeting to a year- round cycle of information in which there's a synergy between what's printed in EyeWorld and what takes place at the meetings." EyeWorld's emphasis on educa- tion has filled a real need and raised the bar for clinical education, Dr. Donnenfeld said. "It has been to my great dismay that the government has forced corporate presentations to stay on message and adhere to the FDA guidelines," he said. "Now with corporate presentations there is no room for education on new concepts or discussion." At such traditional corporate events, it's not possible to T:10.75" B:10.75" INDICATIONS AND USAGE PROLENSA ® (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-infl ammatory drug (NSAID) indicated for the treatment of postoperative infl ammation and reduction of ocular pain in patients who have undergone cataract surgery. IMPORTANT SAFETY INFORMATION ABOUT PROLENSA ® • PROLENSA ® contains sodium sulfi te, a sulfi te that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfi te sensitivity in the general population is unknown and probably low. Sulfi te sensitivity is seen more frequently in asthmatic than in non-asthmatic people. • All topical nonsteroidal anti-infl ammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. • There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Use with caution in patients who have previously exhibited sensitivities to these drugs. • There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. Use with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time. • Use of topical NSAIDs may result in keratitis. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health. Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Post-marketing experience with topical NSAIDs suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events. • PROLENSA ® should not be instilled while wearing contact lenses. The preservative in PROLENSA ® , benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of PROLENSA ® . • The most commonly reported adverse reactions in 3%-8% of patients were anterior chamber infl ammation, foreign body sensation, eye pain, photophobia, and blurred vision. Please see brief summary of full Prescribing Information for PROLENSA ® on adjacent page. References: 1. PROLENSA Prescribing Information, April 2013. 2. Data on fi le, Bausch & Lomb Incorporated. 3. Baklayan GA, Patterson HM, Song CK, Gow JA, McNamara TR. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand white rabbits. J Ocul Pharmacol Ther. 2008;24(4):392-398. PROLENSA is a registered trademark of Bausch & Lomb Incorporated or its affi liates. © Bausch & Lomb Incorporated. All rights reserved. Printed in USA. PRA.0188.USA.15 The PROLENSA ® Effect POWERED FOR PENETRATION Advanced Formulation to Facilitate Corneal Penetration 1-3 pH e ffect Hal og en a ti on e ffect PROLENSA ® delivers potency and corneal penetration with QD dosing at a low concentration 1-3 continued on page 16

• Cover